Two numbers define the end of CVS Omnicare: $949 million, the fraud judgment that sank it, and $250 million, what it fetched for its business operations. The bottom line is a bankruptcy judge in Texas has now signed off on winding the company down.
Judge Stacey G. C. Jernigan of the U.S. Bankruptcy Court for the Northern District of Texas approved the plan. Seeking Alpha reported that she noted it had won “overwhelming acceptance” from general unsecured creditors.
Omnicare supplies pharmacy services to nursing homes, assisted living centers and long-term care and rehab facilities. CVS bought it in 2015. It filed for Chapter 11 in September 2025, only months after a court hit it with the $949 million judgment. The finding: it had dispensed drugs to elderly and disabled patients without valid prescriptions and billed federal healthcare programs for millions of false claims.
Before the wind-down was approved, Omnicare also reached a $440 million deal with the Justice Department to resolve the improper billing case.
A drugstore model under strain
The Omnicare case lands while the whole sector is struggling. Rite Aid has closed every one of its stores. CVS and Walgreens, between them, have shut thousands.
The Financial Times described the squeeze this way: pharmacy counters are being hit by stingier drug reimbursement rates and pharmacist wages, while sales of everything from greeting cards to cosmetics face cut-price competition. Shoppers can also have much of what used to draw them into a CVS delivered, and online services, Amazon among them, now fill prescriptions.
“The whole drugstore four-wall economic model is collapsing on itself, in my opinion,” Josh Cummings, a portfolio manager at Janus Henderson Investors, told the paper.
